| 2024-04-24 20:19 | CC:ATE | Antibe Therapeutics Inc (2) | 0.295 | Shares Delisted from TSX222 | Antibe Therapeutics to be delisted from TSX May 24 |
| 2024-04-24 13:43 | CC:ATE | Antibe Therapeutics Inc (2) | 0.295 | News Release200 | Antibe's CCAA proceedings ended, receiver appointed |
| 2024-04-19 11:23 | CC:ATE | Antibe Therapeutics Inc (2) | 0.295 | News Release200 | Antibe Therapeutics obtains CCAA stay extension |
| 2024-04-16 17:10 | CC:ATE | Antibe Therapeutics Inc (2) | 0.295 | News Release200 | Antibe Therapeutics under review for listing on TSX |
| 2024-04-09 19:06 | CC:ATE | Antibe Therapeutics Inc (2) | 0.295 | News Release200 | Antibe Therapeutics granted initial order under CCAA |
| 2024-04-09 16:24 | CC:ATE | Antibe Therapeutics Inc (2) | 0.295 | Miscellaneous270 | Antibe Therapeutics under TSX delisting review |
| 2024-04-09 09:35 | CC:ATE | Antibe Therapeutics Inc (2) | 0.295 | News Release200 | Antibe to file for initial order under CCAA |
| 2024-04-09 09:17 | CC:ATE | Antibe Therapeutics Inc (2) | 0.295 | Halt Trading170 | Antibe Therapeutics halted at the open |
| 2024-04-01 09:42 | CC:ATE | Antibe Therapeutics Inc (2) | 0.45 | News Release200 | Antibe's otenaproxesul placed on clinical hold by FDA |
| 2024-03-04 09:29 | CC:ATE | Antibe Therapeutics Inc (2) | 0.97 | News Release200 | Antibe ordered to refund Nuance's $20M (U.S.) payment |
| 2024-02-14 11:31 | CC:ATE | Antibe Therapeutics Inc (2) | 0.89 | News Release200 | Antibe spends $2.3-million on R&D in Q3 2024 |
| 2024-02-14 06:35 | CC:ATE | Antibe Therapeutics Inc (2) | 0.89 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-02-14 06:24 | CC:ATE | Antibe Therapeutics Inc (2) | 0.89 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-02-01 10:22 | CC:ATE | Antibe Therapeutics Inc (2) | 1.01 | News Release200 | Antibe extends early warrant exercise incentive program |
| 2023-12-29 09:41 | CC:ATE | Antibe Therapeutics Inc (2) | 0.94 | News Release200 | Antibe arranges early warrant exercise program |
| 2023-12-12 10:43 | CC:ATE | Antibe Therapeutics Inc (2) | 0.70 | News Release200 | Antibe Therapeutics extends warrants to 2024 |
| 2023-11-13 11:37 | CC:ATE | Antibe Therapeutics Inc (2) | 0.93 | News Release200 | Antibe spends $3.5M on R&D in fiscal Q2 2024 |
| 2023-11-13 06:36 | CC:ATE | Antibe Therapeutics Inc (2) | 0.93 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2023-11-13 06:34 | CC:ATE | Antibe Therapeutics Inc (2) | 0.93 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-11-09 10:21 | CC:ATE | Antibe Therapeutics Inc (2) | 1.18 | News Release200 | Antibe talks PK results of otenaproxesul study |
| 2023-11-01 10:09 | CC:ATE | Antibe Therapeutics Inc (2) | 0.69 | News Release200 | Antibe completes initial study of otenaproxesul for pain |
| 2023-10-18 09:14 | CC:ATE | Antibe Therapeutics Inc (2) | 0.45 | News Release200 | Antibe Therapeutics begins otenaproxesul PK/PD study |
| 2023-09-28 09:35 | CC:ATE | Antibe Therapeutics Inc (2) | 0.465 | News Release200 | Antibe receives OK to begin PK/PD otenaproxesul study |
| 2023-09-08 17:46 | CC:ATE | Antibe Therapeutics Inc (2) | 0.56 | News Release200 | Antibe shareholders approve AGM resolutions |
| 2023-08-14 13:35 | CC:ATE | Antibe Therapeutics Inc (2) | 0.57 | News Release200 | Antibe spends $3.6-million on R&D in fiscal Q1 2024 |
| 2023-08-14 06:09 | CC:ATE | Antibe Therapeutics Inc (2) | 0.55 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2023-06-29 13:00 | CC:ATE | Antibe Therapeutics Inc (2) | 0.47 | News Release200 | Antibe spends $11.3-million on R&D in fiscal 2023 |
| 2023-06-29 07:04 | CC:ATE | Antibe Therapeutics Inc (2) | 0.48 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2023-06-29 07:03 | CC:ATE | Antibe Therapeutics Inc (2) | 0.48 | SEDAR MD & A815 | SEDAR MD & A |
| 2023-06-29 07:02 | CC:ATE | Antibe Therapeutics Inc (2) | 0.48 | SEDAR Annual Information Form802 | SEDAR Annual Information Form |